Skip to content
HomeLatest newsHealth & wellnessA reason to smile: new study looks at gum disease and the potential benefits of flossing
Man flossing

A reason to smile: new study looks at gum disease and the potential benefits of flossing

In time for National Dental Hygiene Month, we’re sharing the findings of a recent report that counters claims that the habit has no health benefits.

“Forget you, flossing!”

That was the message many people got after the Associated Press released a report last year that showed a lack of evidence to support the medical benefits of flossing.

But recent research conducted by the Janssen Research & Development Department of Epidemiology and Johnson & Johnson Consumer, Inc. has found that flossing is associated with a lower prevalence of periodontitis.

Researchers found that people who flossed once or more each week were 17% less likely to have gum disease than those who flossed less frequently.

Unspooling the study findings

The study, published in the Journal of Clinical Periodontology, placed participants into three categories: those who flossed or used an interdental brush (a small brush used to clean between your teeth) zero to one time per week, two to four times a week, and five or more times each week.

After researchers adjusted for factors like age, gender and smoking, they found that people who flossed once or more each week were 17% less likely to have gum disease than those who flossed less frequently. They also determined that flossing one or more days a week reduced the risk for periodontitis by 23%, compared to not flossing at all.

Since this was a cross-sectional study—meaning it didn’t track subjects over a long period of time—a direct cause-and-effect relationship between flossing and gum disease could not be proven.

Nevertheless “it provides some assurance that there may be some benefit to flossing,” says the study’s co-author, Mike Lynch, D.M.D., Ph.D., Global Director of Oral Care and Fellow, Global Scientific Engagement, Johnson & Johnson.

So keep at it—your mouth may thank you later.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.